Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises IRLAB Therapeutics in connection with share issues
Mandate

Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019 Capital Markets and Public M&A

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Related

Vinge advises TSG on the acquisition of Processkontroll GT

 TSG, a European leader in technical services for sustainable mobility solutions and critical energy infrastructure, has acquired Processkontroll GT, a specialist in compressed and liquid gas infrastructure.
June 01, 2026

Vinge has advised Mirova with the financing of the Fågelås, Dållebo, and Boarp wind farms

 The financing, provided by Danske Bank and La Banque Postale, consists of multiple facilities totalling approximately EUR 100 million, including, among other things, a long-term amortising loan and guarantee facilities.
June 01, 2026

Vinge has advised Nordion Energi AB in connection with the acquisition of shares in Kalmar Energi

 Nordion Energi acquires E.ON Sverige AB’s entire stake in Kalmar Energi and in connection with the completion of such, divest Kalmar Energi’s electricity retail business to Siljansvik AB (publ).
May 29, 2026